Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05786716
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:54.072472+00:00
Published At
2025-12-02T00:00:00+00:00
Record Updated At
2025-12-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Haematological Malignancy", "Colorectal Neoplasms", "Urinary Bladder Neoplasm", "Gallbladder Neoplasms", "Salivary Gland Neoplasm", "Lung Neoplasm", "Pancreatic Neoplasm", "Ovarian Neoplasms", "Prostatic Neoplasm", "Skin Neoplasm", "Solid Tumour"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-02"
protocolSection.identificationModule.nctId
"NCT05786716"
protocolSection.identificationModule.officialTitle
"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations."
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2", "PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Haematological Malignancy (protocolSection.conditionsModule.conditions)
  • Colorectal Neoplasms (protocolSection.conditionsModule.conditions)
  • Urinary Bladder Neoplasm (protocolSection.conditionsModule.conditions)
  • Gallbladder Neoplasms (protocolSection.conditionsModule.conditions)
  • Salivary Gland Neoplasm (protocolSection.conditionsModule.conditions)
  • Lung Neoplasm (protocolSection.conditionsModule.conditions)
  • Pancreatic Neoplasm (protocolSection.conditionsModule.conditions)
  • Ovarian Neoplasms (protocolSection.conditionsModule.conditions)
  • Prostatic Neoplasm (protocolSection.conditionsModule.conditions)
  • Skin Neoplasm (protocolSection.conditionsModule.conditions)
  • Solid Tumour (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.